Evidence map›Paper›PMID 42110610›Full record

ArticleArchives of medical science : AMS2026

Association of genetic polymorphisms on methotrexate toxicity in patients with rheumatoid arthritis.

María José Zarzuelo Romero, María Del Mar Maldonado Montoro, Cristina Pérez Ramírez, Noelia Márquez Pete, Almudena Sánchez Martín, Fernando Martínez Martínez, Miguel Ángel Calleja Hernández, María Carmen Ramírez Tortosa, Alberto Jiménez Morales

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of medical science : AMS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Biomedicines · 2023
    Article
  2. The impact of single nucleotide polymorphisms inArchives of medical science : AMS · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

María José Zarzuelo RomeroDepartment of Pharmacy and Pharmaceutical Technology, Social and Legal Assistance Pharmacy Section, Faculty of Pharmacy, University of Granada, Granada, Spain.
María Del Mar Maldonado MontoroClinical Analysis Service, Hospital Campus de la Salud, Granada, Spain.
Cristina Pérez RamírezPharmacy Service, Pharmacogenetics Unit, University Hospital Virgen Macarena, Sevilla, Spain.
Noelia Márquez PetePharmacy Service, Pharmacogenetics Unit, University Hospital Virgen de las Nieves, UGC Provincial de Farmacia de Granada, Granada, Spain.
Almudena Sánchez MartínPharmacy Service, Pharmacogenetics Unit, University Hospital Virgen de las Nieves, UGC Provincial de Farmacia de Granada, Granada, Spain.
Fernando Martínez MartínezDepartment of Pharmacy and Pharmaceutical Technology, Social and Legal Assistance Pharmacy Section, Faculty of Pharmacy, University of Granada, Granada, Spain.
Miguel Ángel Calleja HernándezPharmacy Service, Pharmacogenetics Unit, University Hospital Virgen Macarena, Sevilla, Spain.
María Carmen Ramírez TortosaDepartment of Biochemistry, Faculty of Pharmacy, University of Granada, Granada, Spain.
Alberto Jiménez MoralesPharmacy Service, Pharmacogenetics Unit, University Hospital Virgen de las Nieves, UGC Provincial de Farmacia de Granada, Granada, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Methotrexate (MTX) is the treatment of choice for patients with rheumatoid arthritis (RA). However, it has been found to produce toxicity in some patients. Different polymorphisms can play a part in inter-individual differences in toxicity. Our aim is therefore to determine the influence of gene polymorphisms in the MTX metabolic pathway, such as Material and methods: Real-time polymnerase chain reaction (PCR) analysis with TaqMan probes was performed on these polymorphisms in 200 patients in a retrospective study. Results: Patients with TT genotype and C allele for Conclusions: Pharmacogenomic analysis of these polymorphisms may facilitate decision-making in relation to MTX treatment toxicity among RA patients.

Indexed as

methotrexatepolymorphismsrheumatoid arthritistoxicity

Identifiers

PMID42110610
PMCPMC13154742

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.